Join us to lead the development of therapeutic siRNA oligonucleotides, focusing on disease-targeted optimisation and clinical development. Drive innovation in drug design strategy and collaborate with cross-functional teams. Ideal for experienced scientists with expertise in siRNA/RNAi design and a strong background in molecular biology or bioinformatics.
Dieses Unternehmensprofil wurde automatisch erstellt. Wenn du für Roche Schweiz arbeitest, kannst du das Profil jetzt beanspruchen und verifizieren – kostenlos und in wenigen Minuten.
In Roche’s Pharmaceutical Research and Early Development organization (pRED), teams are united by the mission to transform science into medicines. The Therapeutic Modalities (TMo) organization is accountable for translating disease biology into high-quality drug candidates across small molecules, large molecules, oligonucleotides, and genomic medicines, driving innovation through cross-disciplinary collaboration.